Single-Photon Emission Computerized Tomography in the Diagnosis and Monitoring of Lymphomas
Author:
Чернов В.12, Chernov V.34, Дудникова Е.1, Dudnikova E.3, Гольдберг В.1, Goldberg V.3, Кравчук Т.1, Kravchuk T.3, Данилова А.1, Danilova A.3, Зельчан Р.1, Zel'chan R.3, Медведева А.1, Medvedeva A.3, Синилкин И.1, Sinilkin I.3, Брагина О.1, Bragina O.3, Белевич Ю.1, Belevich Yu.5, Королева Е.6, Koroleva E.7
Affiliation:
1. Национальный исследовательский институт онкологии ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук» 2. Национальный исследовательский Томский политехнический университет 3. Tomsk National Research Medical Center 4. National Research Tomsk Polytechnic University 5. Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science 6. Сибирский государственный медицинский университет 7. Siberian State Medical University
Abstract
Despite the high efficiency of the use of 18F-FDG PET in the diagnosis, staging, monitoring and prognosis of treatment of lymphomas, the use of this method in our country is limited due to the high cost and the insufficient number of PET-centers. In this regard, it seems relevant to conduct research aimed at using known and developing original radiopharmaceuticals for lymphoma imaging with single-photon emission computed tomography (SPECT). In this review, the main radiopharmaceuticals (67Ga-citrate, 201Tl, 199Tl, 99mTc-methoxy-isobutyl-isonitrile, 99mTc-tetrofosmin, 111In-octreotide), which are possible for SPECT lymphoma imaging are shown. Also mechanisms of their action, the possibility of their using for various morphological variants of lymphomas and localizations of the lesion are described. In addition, the results of the use of an innovative radiopharmaceutical based on glucose - 99mTc-1-thio-D-glucose, which is promising for diagnostics, staging and monitoring of lymphoproliferative diseases, are presented.
Publisher
Infra-M Academic Publishing House
Subject
Nuclear Energy and Engineering
Reference49 articles.
1. Aslanidi IP, Mukhortova OV, Shurupova IV, Derevyanko EP, Katunina TA, Pivnik AV, Stroyakovskii DL. Positron emission tomography: refining the stage of the disease in malignant lymphomas. Clinical Oncohematology. Fundamental Research and Clinical Practice. 2010;3(2):119-29. (Russian)., Aslanidi IP, Mukhortova OV, Shurupova IV, Derevyanko EP, Katunina TA, Pivnik AV, Stroyakovskii DL. Positron emission tomography: refining the stage of the disease in malignant lymphomas. Clinical Oncohematology. Fundamental Research and Clinical Practice. 2010;3(2):119-29. (Russian). 2. Chernov VI, Dudnikova EA, Goldberg VE, et al. Positron Emission Tomography in the Diagnosis and Monitoring of Lymphomas. Medical Radiology and Radiation Safety. 2018;63(6):42-50. (Russian)., Chernov VI, Dudnikova EA, Goldberg VE, et al. Positron Emission Tomography in the Diagnosis and Monitoring of Lymphomas. Medical Radiology and Radiation Safety. 2018;63(6):42-50. (Russian). 3. Front D, Israel O. Present state and future role of gallium-67 scintigraphy in lymphoma. J Nucl Med. 1996;37(3):530-2., Front D, Israel O. Present state and future role of gallium-67 scintigraphy in lymphoma. J Nucl Med. 1996;37(3):530-2. 4. Novikov SN, Girshovich MM. Diagnosis and staging of Hodgkin lymphoma. Problems of Tuberculosis and Lung Diseases. 2007;8(2):65-72., Novikov SN, Girshovich MM. Diagnosis and staging of Hodgkin lymphoma. Problems of Tuberculosis and Lung Diseases. 2007;8(2):65-72. 5. Kostakoglu L, Goldsmith S.J. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and followup of lymphoma: is it time to shift gears? Eur J Nucl Med. 2000;27(10):1564-78., Kostakoglu L, Goldsmith S.J. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and followup of lymphoma: is it time to shift gears? Eur J Nucl Med. 2000;27(10):1564-78.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|